- Dr Tim Calvert joins as Vice President of Business Development, Integrated Discovery Services, Europe.
- Dr Michael Donaldson joins as Principal Scientist, Dermal Services.
- Appointments support continued expansion into the Global market.
Manchester, UK, 27 February 2018: Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, today announced it has appointed Dr Michael Donaldson as Principal Scientist in its Dermal department, and Dr Tim Calvert as Vice President of Business Development, Integrated Discovery Services, Europe.
Tim has extensive experience in the delivery of integrated drug discovery and development solutions, supporting organisations ranging from virtual companies to global pharma. Tim joins Concept from Aptuit where he held various roles, most recently Senior Director of Integrated Drug Development, during which time he was responsible for executing complex and accelerated drug development programmes. Prior to joining Aptuit, he was at Lonza, where he led and secured Israel’s first gene therapy development programme, Catalent Pharma Solutions, and Invitrogen.
Michael has over 17 years’ experience in the pharmaceutical development and manufacturing industry. Most recently he was Director of Biology in Dermatology Therapy Area at GlaxoSmithKline. Previous experience includes formulation and manufacturing at Stiefel, a GSK company, development of skin permeation products at MedPharm, and developing liquid chromatography methods for antibiotic production analysis within the QC/QA group at Roche Pharmaceuticals. In his new role at Concept, Michael will be responsible for Dermal Services.
Philip Payne, Chief Commercial Officer, Concept Life Sciences, said: “We are delighted to welcome Michael and Tim to Concept. Their notable scientific and commercial backgrounds will be invaluable in supporting the continued expansion of the group.”